Sanofi can’t even buy a break now, as ri­val No­vo speeds ahead on di­a­betes show­down

Things are just not go­ing Sanofi’s way. Late last week, just a cou­ple of days be­fore Pfiz­er scooped out Medi­va­tion af­ter slam­ming the French phar­ma’s bid to the side­lines, Sanofi had to con­cede that its ap­pli­ca­tion for a Lan­tus-plus-lixise­n­atide com­bo has been de­layed. The FDA now plans to make a de­ci­sion in No­vem­ber so it can take ex­tra time to con­sid­er the fresh da­ta it de­mand­ed to see.

Sanofi’s loss is No­vo’s gain. The Dan­ish phar­ma com­pa­ny looks to be on the in­side track at the FDA af­ter win­ning a unan­i­mous vote at an agency pan­el re­view for Xul­to­phy, its ri­val com­bi­na­tion of Tre­si­ba with its GLP-1 block­buster Vic­toza.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.